42 / 56
Tomo VI Vol. V N˚1-2-3 · 2014 · Santiago - Chile
1.
Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatmentof
persistent corneal epithelial defect by autologous
serumapplication. Ophthalmolgy 1999; 106: 1984-1989.
2.
Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito
I, et al. Treatment of dry eye by autologous serum
application in Sjogren`s syndrome. Br J Ophthalmol
1999; 83: 390-395.
3.
Geerling G, Maclennan S, Hartwig D. Autologous
serumeye drops for ocular surface disorders. Br J
Ophthalmol2004; 88: 1467-1474.
4.
Kruse FE, Tseng SC. Serum differentially modulates
theclonal growth and differentiation of cultured limbal
and corneal epithelium. Invest Ophthalmol Vis Sci
1993; 34:2976-2989.
5.
Van Setten GB, Tervo T, Tervo K, Tarkkanen A.
Epidermalgrowth factor (EGF) in ocular fluids: presence,
origin and therapeutical considerations. Acta Ophthalmol
Suppl 1992; 202: 54-59.
6.
Pastor JC, Calonge M. Epidermal growth factor and
cornealwound healing. A multicenter study. Cornea
1992;11: 311-314.
7.
Collins MK, Perkins GR, Rodriguez-Tarduchy G, NietoMA,
Lopez-Rivas A. Growth factors as survival factors:
regulation of apoptosis. Bioessays 1994; 16: 133-138.
8.
Ohashi Y, Motokura M, Kinoshita Y, Mano T,
WatanabeH, Kinoshita S, et al. Presence of epidermal
growth factorin human tears. Invest Ophthalmol Vis
Sci 1989; 30:1879-1882.
9.
Yoshino K, Garg R, Monroy D, Ji Z, Pflugfelder SC.
Productionand secretion of transforming growth factor
beta(TGF-beta) by the human lacrimal gland. Curr Eye
Res1996; 15: 615-624.
10. Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi
A, Shimazaki J, et al. Albumin as a tear supplement
in the treatmentof severe dry eye. Br J Ophthalmol
2003; 87:1279-1283.
11. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels
JT. Autologous serum eyedrops for dry eyes and
epithelialdefects: clinical and in vitro toxicity studies.
Br J Ophthalmol
2001; 85: 1188-1197
.
12. Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin.
A new therapy for corneal trophic ulcer. Arch
Ophthalmol1983; 101:1046-1048.
13. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis
MJ,Murphy CJ. Synergistic effects of substance P with
insulin-like growth factor-1 on epithelial migration of
the cornea. J Cell Physiol 1996; 169: 159-166.
14. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T,
Ishida R, Tsubota K. Autologous serum application in the
treatmentof neurotrophic keratopathy. Ophthalmology
2004; 111: 1115-1120.
15. del Castillo JM, de la Casa JM, Sardina RC, FernandezRM,
Feijoo JG, Gomez AC, et al. Treatment of recurrent
corneal erosions using autologous serum. Cornea
2002;21: 781-783.
16. Tsubota K, Satake Y, Ohyama M, Toda I, Takano Y,Ono
M, et al. Surgical reconstruction of the ocular surface
in advanced ocular cicatricial pemphigoid and Stevens-
Johnson syndrome. Am J Ophthalmol 1996;122: 38-52.
17. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima
Y, Watanabe R, et al. Autologous serum eye drops for
the treatmentof severe dry eye in patients with chronic
graft-versus host disease. Bone Marrow Transplant
2003; 31: 579-583.
18. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC,
deSouza CA. GVDH dry eyes treated with autologous
serumtears. Bone Marrow Transplant 2000; 25: 1101-1103.
19. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment
of superior limbic keratoconjunctivitis by application
of autologous serum. Cornea 2001; 20: 807-810.
BIBLIOGRAFÍA
amniótica, queratopatía penetrante en
pacientes con síndrome de Stevens-Johnson
o penfigoide ocular cicatricial, contribuyendo
a la estabilidad del epitelio corneal
16
, como
también en el manejo del ojo seco asociado
a enfermedad injerto contra huésped, en
donde se encuentra una mejoría clínica
subjetiva muy rápida
17
, siendo algo más lenta
la desaparición de la queratopatía punctata
18
.
En el tratamiento de la úlcera de Mooren y
de la queratoconjuntivitis límbica superior,
algunos autores han encontrado una respuesta
adecuada al tratamiento en más del 80% de
los pacientes
19
.